Crinetics Pharmaceuticals(CRNX) - 2021 Q1 - Quarterly Report

Financial Performance - For the three months ended March 31, 2021, Crinetics Pharmaceuticals reported a net loss of $22.9 million, compared to a net loss of $17.4 million for the same period in 2020, representing a 31% increase in losses year-over-year[11]. - Total operating expenses for the first quarter of 2021 were $22.9 million, up from $17.9 million in the first quarter of 2020, indicating a 28% increase[11]. - Net cash used in operating activities for Q1 2021 was $20.1 million, compared to $12.2 million in Q1 2020, marking a 64% increase in cash burn[18]. - The company expects to continue incurring net losses for the foreseeable future and will need to raise substantial additional capital to support its business plan[25]. - The company reported an accumulated deficit of $190.5 million as of March 31, 2021, with net losses expected to increase substantially due to ongoing clinical trials and research activities[86]. Research and Development - Research and development expenses increased to $17.6 million in Q1 2021 from $13.9 million in Q1 2020, reflecting a 27% rise[11]. - The company plans to substantially increase research and development expenses in the foreseeable future to support ongoing product candidate development[94]. - Paltusotine, the lead product candidate, is in Phase 3 trials for acromegaly, with top-line data expected in 2023, which could support registration in the U.S. and Europe[79]. - CRN04777, an investigational drug for congenital hyperinsulinism, is undergoing a Phase 1 study, with preliminary data expected in mid-2021[80]. - CRN04894, aimed at treating diseases caused by excess ACTH, is also in a Phase 1 study, with preliminary data anticipated in the second half of 2021[81]. Cash and Investments - As of March 31, 2021, the company had $150.7 million in unrestricted cash, cash equivalents, and investment securities, which is expected to meet funding requirements for at least the next 12 months[25]. - Cash, cash equivalents, and restricted cash at the end of Q1 2021 totaled $106.1 million, up from $51.4 million at the end of Q1 2020[18]. - Total available-for-sale investment securities as of March 31, 2021, amounted to $45.086 million, down from $77.793 million at December 31, 2020[49][50]. - The fair market value of U.S. government and agency obligations was $42.181 million as of March 31, 2021, with gross unrealized losses of $2, compared to $74.223 million with gross unrealized losses of $5 at December 31, 2020[49][50]. - The Company has not recognized any impairment in its financial statements related to its available-for-sale investment securities as of March 31, 2021[51]. Capital Raising - The company raised an additional $72.5 million through a follow-on offering of 4,562,044 shares in April 2021[25]. - The company completed a public offering of 8,222,500 shares at a price of $14.00 per share, raising approximately $107.9 million net of costs[61]. - The company completed a follow-on offering of 4,562,044 shares at $16.44 per share, raising net proceeds of approximately $72.5 million after costs[72]. - The company expects to finance its cash needs through equity offerings, debt financings, or other capital sources, which may dilute stockholder ownership[103]. Expenses and Liabilities - General and administrative expenses rose to $5.3 million for the three months ended March 31, 2021, up from $4.0 million in the same period in 2020, primarily due to increased personnel and legal expenses[98]. - Stock-based compensation expense totaled $3.4 million for the three months ended March 31, 2021, compared to $2.1 million for the same period in 2020, representing a 58.7% increase[70]. - The company reported future minimum payments under non-cancellable operating leases totaling $5,486,000 as of March 31, 2021[59]. Operational Outlook - The company is assessing the impact of COVID-19 on its operations, including clinical trials and timelines, which may affect future forecasts[85]. - The company has not generated any revenues from commercial sales of approved products and does not expect to do so in the foreseeable future[89]. - The company anticipates that general and administrative expenses will increase to support continued research and development and potential commercialization activities[95]. Legal and Compliance - The company does not expect any ongoing litigation to have a material adverse effect on its financial position or results of operations[60]. - There are currently no material legal proceedings involving the company, although it may be subject to claims in the ordinary course of business[114]. - The company has not made any unregistered sales of equity securities during the reporting period[115]. - The company has no off-balance sheet arrangements as defined under applicable SEC rules[106].